Intézmény
Institute of Hematology & Blood Diseases Hospital
Más néven: Institute of Hematology and Blood Diseases Hospital · 中国医学科学院血液病医院
- 152futó vizsgálat
- 37lezárt vizsgálat
- 7003publikáció (OpenAlex)
Futó vizsgálatok
Még nem toboroz
Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Még nem toboroz
Még nem toboroz
Study of SGB-9768 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Még nem toboroz
Toboroz
Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
Meghívásos bevonás
Még nem toboroz
A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma
Toboroz
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Még nem toboroz
Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients
Toboroz
Fut, nem toboroz
Toboroz
SG301-SC Injection Safety Study in Subjects With Primary ITP Patients
Toboroz
Még nem toboroz
Még nem toboroz
Még nem toboroz
Fut, nem toboroz
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
Toboroz
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Toboroz
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Toboroz
Toboroz
Toboroz
Még nem toboroz
Toboroz
Toboroz
A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis
Még nem toboroz
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
Toboroz
Még nem toboroz
Toboroz
IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
Toboroz
Még nem toboroz
Meghívásos bevonás
Toboroz
Toboroz
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
Toboroz
Using Mobile Technology-assisted Outpatient Maintenance Therapy Pediatric ALL
Toboroz
Még nem toboroz
Még nem toboroz
Toboroz
Toboroz
Még nem toboroz
Toboroz
Toboroz
Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
Toboroz
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
Toboroz
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Toboroz
Még nem toboroz
Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
Toboroz
Toboroz
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
Toboroz
Showing 50 of 152.
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
- Mielóma multiplex28 toboroz
- Akut limfoid leukémia (ALL)22 toboroz
- Akut mieloid leukémia (AML)19 toboroz
- Gyermekkori daganatok16 toboroz
- Immune thrombocytopenia (ITP)11 toboroz
- Hemofília9 toboroz
- Krónikus limfoid leukémia (CLL)6 toboroz
- Mieloproliferatív neopláziák6 toboroz
- Lupus (SLE)5 toboroz
- Mielodiszplasztikus szindróma (MDS)5 toboroz
- ANCA-asszociált vasculitis4 toboroz
- Aplastic anaemia4 toboroz
- Diffúz nagy B-sejtes limfóma (DLBCL)4 toboroz
- Follikuláris limfóma4 toboroz
- Köpenysejtes limfóma4 toboroz
- Szisztémás szklerózis (szkleroderma)4 toboroz
- Antiphospholipid syndrome3 toboroz
- Dermatomyositis and polymyositis (myositis)2 toboroz
- Amiloidózis1 toboroz
- Amiotrófiás laterálszklerózis (ALS)1 toboroz
- Cytomegalovirus infection1 toboroz
- Krónikus mieloid leukémia (CML)1 toboroz
- Rheumatoid arthritis1 toboroz
- Sjögren-szindróma1 toboroz
- Thalassaemia1 toboroz
Lezárt vizsgálatok
Visszavonták
Visszavonták
Lezárult
Lezárult
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Toboroz
Lezárult
Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)
Leállították
Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients
Lezárult
Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
Visszavonták
Lezárult
Lezárult
Lezárult
Leállították
Lezárult
A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus
Leállították
Lezárult
Lezárult
Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL
Lezárult
CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies
Lezárult
BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma
Lezárult
Lezárult
Lezárult
A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors
Leállították
Lezárult
Leállították
Lezárult
Clinical Study of UC-MSC Combined With Immunosuppressive Agents in the Treatment of Pediatric HAAA
Leállították
A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-Thalassaemia
Lezárult
A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma
Lezárult
Leállították
Lezárult
Lezárult
Lezárult
Lezárult
Lezárult
Lezárult
Lezárult
Regiszterbeli névváltozatok (39)
A vizsgálati regiszterek ezeken a neveken tartják nyilván az intézményt. Minden sor egy regiszterbejegyzés: a címe és az alatta nyilvántartott vizsgálatok.
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality 300020
68 vizsgálat
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, 300000
29 vizsgálat
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin, China 300041
20 vizsgálat
Institute of Hematology and Blood Diseases Hospital
Tianjin, 300320
8 vizsgálat
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Tianjin, Tianjin Municipality 300020
7 vizsgálat
Institute of Hematology & Blood Diseases Hospital, China
Tianjin, 300000
7 vizsgálat
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS)
Tianjin, Tianjin Municipality 301600
5 vizsgálat
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC
Tianjin, Tianjin Municipality 300020
4 vizsgálat
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch
Tianjin, Tianjin Municipality 301617
4 vizsgálat
Institute of Hematology and Blood Diseases Hospital, Tianjin-Hematology
Tianjin, Tianjin Municipality 300020
4 vizsgálat
Tianjin Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality 301636
4 vizsgálat
Institute of Hematology & Blood Diseases Hospital
Tianjing
2 vizsgálat
Contact: Lu gui Qiu Doctor
Contact: Zimin Sun
Institute of Hematology and Blood Diseases Hospital
Beijing
1 vizsgálat
NCT06232096A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
Contact: Lugui Qiu, Doctor
Institute of Hematology and Blood Diseases Hospital
Xiaobailou, Tianjin Municipality 300020
1 vizsgálat
NCT05101187Olorofim Aspergillus Infection Study
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
Tianjin
1 vizsgálat
NCT06900088Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
Contact: Erlie jiang
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin, Tianjin 300020
Tianjin, Tianjin Municipality 300020
1 vizsgálat
Institute of Hematology and Blood Diseases Hospital
Tianjin, Tianjin Municipality 300020
1 vizsgálat
Institute of Hematology and Blood Diseases Hospital
Tianjin, Tianjin Municipality 300020
1 vizsgálat
Institute of Hematology and Blood Diseases Hospital, Tianjin, China
Tianjin, 300020
1 vizsgálat
NCT07137637HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Contact: Mingyuan Sun, MD
Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences and Pek
Tianjin, 510080
1 vizsgálat
Institute of Hematology & Blood Diseases Hospital
Beijing
1 vizsgálat
Contact: Erlie Jiang, M.D.;Ph.D
Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC
Tianjin, Tianjin Municipality 300020
1 vizsgálat
NCT06244368GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
Contact: Wei Liu
Institute Of Hematology&Blood Diseases Hospital,Chinese Academy Of Medicai Sciences
Tianjin, Tianjin Municipality 300000
1 vizsgálat
Contact: Xiaofan Zhu, M.D
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc
Tianjin, Tianjin Municipality 300020
1 vizsgálat
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc
Tianjin, Tianjin Municipality 300020
1 vizsgálat
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc
Tianjin, Tianjin Municipality 300020
1 vizsgálat
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc
Tianjin, Tianjin Municipality 300020
1 vizsgálat
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc
Tianjin, Tianjin Municipality 300020
1 vizsgálat
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc
Tianjin, Tianjin Municipality 300020
1 vizsgálat
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc
Tianjin, Tianjin Municipality 300020
1 vizsgálat
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc
Tianjin, Tianjin Municipality 300020
1 vizsgálat
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc
Tianjin, Tianjin Municipality 300020
1 vizsgálat
Institute of Hematology &Blood Diseases Hospital ,Chinese Academy of medical science & Peking Union Medical College
Tianjin
1 vizsgálat
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Tianjin, Tianjin Municipality
1 vizsgálat
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences - Investigational Site Number: 15602
Tianjin, Tianjin Municipality 300020
1 vizsgálat
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Unio (Site 2800)
Tianjin, Tianjin Municipality 301617
1 vizsgálat
Contact: Study Coordinator
Institute of Institute of Hematology & Blood Diseases Hospital (Chinese Academy of Medical Sciences)
Tianjin
1 vizsgálat
Contact: jianxiang Wang, MD
National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin
1 vizsgálat
NCT07620275Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
Contact: Lugui Qiu, M.D.
The Institute of Hematology & Blood Diseases Hospital (Chinese Academy of Medical Sciences)
Tianjin, Tianjin Municipality 300020
1 vizsgálat
Contact: Fengkui Zhang, Dr.
Betegségek
Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.
- Akut mieloid leukémia (AML)65 munka · 30 vizsgálat
- Akut limfoid leukémia (ALL)47 munka · 27 vizsgálat
- Mielóma multiplex32 munka · 40 vizsgálat
- Mieloproliferatív neopláziák27 munka · 9 vizsgálat
- Immune thrombocytopenia (ITP)21 munka · 14 vizsgálat
- Hemofília19 munka · 20 vizsgálat
- Aplastic anaemia18 munka · 5 vizsgálat
- Krónikus limfoid leukémia (CLL)17 munka · 10 vizsgálat
- Krónikus mieloid leukémia (CML)16 munka · 1 vizsgálat
- Mielodiszplasztikus szindróma (MDS)14 munka · 6 vizsgálat
- Diffúz nagy B-sejtes limfóma (DLBCL)10 munka · 9 vizsgálat
- Köpenysejtes limfóma5 munka · 7 vizsgálat
Intézményadatok: ROR 04n16t016 (CC0-1.0)Frissítve: 2026. nov. 15.